Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
The field of toxicology is currently undergoing a global paradigm shift to use of in vitro approaches for assessing the risks of chemicals and drugs in a more mechanistic and high throughput manner than current approaches relying primarily on in vivo testing. However, reliance on in vitro data entails a number of new challenges associated with translating the in vitro results to corresponding in vivo exposures. Physiologically based pharmacokinetic (PBPK) modeling provides an effective framework for conducting quantitative in vitro to in vivo extrapolation (QIVIVE). Their physiological structure facilitates the incorporation of in silico- and in vitro-derived chemical-specific parameters in order to predict in vivo absorption, distribution, metabolism and excretion. In particular, the combination of in silico- and in vitro parameter estimation with PBPK modeling can be used to predict the in vivo exposure conditions that would produce chemical concentrations in the target tissue equivalent to the concentrations at which effects were observed with in vitro assays of tissue/organ toxicity. This review describes the various elements of QIVIVE and highlights key aspects of the process, with an emphasis on extrapolation of in vitro metabolism data to predict in vivo clearance as the key element. Other important elements include characterization of free concentration in the toxicity assay and potential complications associated with intestinal absorption and renal clearance. Examples of successful QIVIVE approaches are described ranging from a simple steady-state approach that is suitable for a high throughput environment to more complicated approaches requiring full PBPK models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873 · cited 1×
“…description of clearance of a drug compound from blood by liver metabolism (Gillette, 1971; Rowland et al., 1973; Wilkinson and Schenker, 1975; Wilkinson and Shand, 1975), binding in the blood is assumed to be linear and the fraction unbound, fub, is simply multiplied by the intrinsic hepatic…”
BackgroundDetermination of drug permeability and prediction of drug absorption in Caco-2 monolayers
Hubatsch, I., Ragnarsson, E. G. E., & Artursson, P. (2007) · Nature Protocols · doi:10.1038/nprot.2007.303 · Cited by 1,499 · cited 1×
“The human colon carcinoma cell line Caco-2 has been widely used in drug development area as a model of human intestine, especially as a model for absorption (Sambuy et al., 2005; Hubatsch et al., 2007).”
BackgroundSambuy, Y., De Angelis, I., Ranaldi, G., Scarino, M. L., Stammati, A., & Zucco, F. (2005) · Cell Biology and Toxicology · doi:10.1007/s10565-005-0085-6 · Cited by 1,488 · cited 1×
“The human colon carcinoma cell line Caco-2 has been widely used in drug development area as a model of human intestine, especially as a model for absorption (Sambuy et al., 2005; Hubatsch et al., 2007).”
BackgroundPhysiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,415 · cited 3×
“However, the physiological mammalian structure (tissue volumes, blood flows, ventilation rate, glomerular filtration rate, etc.) is well characterized (Arms and Travis, 1988; Brown et al., 1997), and there is really no difficulty in describing tissues separately when necessary.”
BackgroundMethodObach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870 · cited 2×
“CYP3A4, the major CYP isoform in human enterocytes, has been the focus of a great deal of research in the pharmaceutical area (i) as a contributor to low oral bioavailability and (ii) as a major source of interindividual variability due to variable constitutive expression and potential drug-drug interactions (Shen et…”
BackgroundHewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Clearance concepts in pharmacokinetics
Rowland, M., Benet, L. Z., & Graham, G. G. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059626 · Cited by 649 · cited 2×
“…of chemical availability for clearance In the standard description of clearance of a drug compound from blood by liver metabolism (Gillette, 1971; Rowland et al., 1973; Wilkinson and Schenker, 1975; Wilkinson and Shand, 1975), binding in the blood is assumed to be linear and the fraction…”
BackgroundThe Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533 · cited 1×
“A number of software platforms are available to support generic PBPK modeling for pharmaceuticals using in vitro metabolism data, as exemplified by the Simcyp platform (Rostami-Hodjegan and Tucker, 2007; Jamei et al., 2009).”
MethodSimulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530 · cited 2×
“In this case, to properly account for variability for data obtained from recombinant enzyme systems, additional information on enzyme abundance is required (Rostami-Hodjegan and Tucker, 2007).”
BackgroundMethodWetmore, B. A., Wambaugh, J. F., Ferguson, S. S., Sochaski, M. A., Rotroff, D. M., Freeman, K., Clewell, H. J., Dix, D. J., Andersen, M. E., Houck, K. A., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr254 · Cited by 415 · cited 1×
“Each of these areas is the subject of ongoing research, but at the moment QIVIVE calculations can be associated with uncertainties of more than an order of magnitude (Rotroff et al., 2010; Wetmore et al., 2011).”
BackgroundSelf-citationPrediction of Intestinal First-Pass Drug Metabolism
Yang, J., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109733 · Cited by 366
Human Carboxylesterase Isozymes: Catalytic Properties and Rational Drug Design
Imai, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.173 · Cited by 359 · cited 3×
“Before a full implementation, however, more studies should be performed to address the known differences in enzyme expressions between Caco-2 and human intestine in vivo, not just for the expression of the specific enzyme itself, but also the relative level of expression of the enzyme compared to other enzymes and als…”
BackgroundGeneral approach for the calculation of tissue to plasma partition coefficients
Schmitt, W. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.09.010 · Cited by 349 · cited 2×
“E-mail: HClewell@thehamner.org (Received 17 October 2011; revised 25 April 2012; accepted 06 May 2012) 1040-8444 1547-6898 © 2012 Informa Healthcare USA, Inc. 10.3109/10408444.2012.692115 Critical Reviews in Toxicology”
BackgroundInfluentialFACTORS AFFECTING DRUG METABOLISM
Gillette, J. R. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb46890.x · Cited by 348 · cited 2×
“The parameters in a PBPK model can be categorized into four types: exposure, physiological, partitioning, and metabolism.”
BackgroundEnzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318 · cited 4×
“CYP3A4, the major CYP isoform in human enterocytes, has been the focus of a great deal of research in the pharmaceutical area (i) as a contributor to low oral bioavailability and (ii) as a major source of interindividual variability due to variable constitutive expression and potential drug-drug interactions (Shen et…”
BackgroundInfluentialPrediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver Slices
Brian Houston, J., & Carlile, D. J. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709002237 · Cited by 306 · cited 2×
“E-mail: HClewell@thehamner.org (Received 17 October 2011; revised 25 April 2012; accepted 06 May 2012) 1040-8444 1547-6898 © 2012 Informa Healthcare USA, Inc. 10.3109/10408444.2012.692115 Critical Reviews in Toxicology”
BackgroundInfluentialProgress in the reduction, refinement and replacement of animal experimentation
Balls, M., van Zeller, A.-M., & Halder, M. (2000) · DigitalGeorgetown (Georgetown University Library) · Cited by 296
McGinnity, D. F., Soars, M. G., Urbanowicz, R. A., & Riley, R. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000026 · Cited by 274 · cited 2×
“…isolated cells are generally considered to be a superior in vitro system, cryopreserved hepatocytes have become a prevalent alternative due to the limited availability of fresh cells, especially for large-scale screening purposes (Soars et al., 2002; McGinnity et al., 2004; Chiba et al., 2009).”
BackgroundIncorporating Human Dosimetry and Exposure into High-Throughput In Vitro Toxicity Screening
Rotroff, D. M., Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., LeCluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq220 · Cited by 250 · cited 2×
“Two recent studies have evaluated the possibility of applying a simple QIVIVE approach to interpret the results of high throughput assays conducted under the EPA ToxCast program (Rotroff et al., 2010, Wetmore BA, 2011).”
BackgroundMethodSelf-citationHuman hepatocytes as a tool for studying toxicity and drug metabolism
Gomez-Lechon, M., Donato, M., Castell, J., & Jover, R. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489424 · Cited by 242 · cited 2×
“At present, isolated hepatocytes in suspension appear to provide the most practical in vitro Critical Reviews in Toxicology metabolism system that closely reflects in vivo conditions (Gomez-Lechon et al., 2003; Kedderis, 2007; Hewitt et al., 2007).”
BackgroundIn Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance
Soars, M. G., Burchell, B., & Riley, R. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 228 · cited 3×
“…isolated cells are generally considered to be a superior in vitro system, cryopreserved hepatocytes have become a prevalent alternative due to the limited availability of fresh cells, especially for large-scale screening purposes (Soars et al., 2002; McGinnity et al., 2004; Chiba et al., 2009).”
BackgroundPrediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development
Chiba, M., Ishii, Y., & Sugiyama, Y. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9103-6 · Cited by 228 · cited 4×
“There have been significant improvements in the quality of human tissue preparation in recent years and also parallel advances in application strategies of those in vitro data to predict in vivo kinetics (Gomez-Lechon et al., 2007; Houston and Galetin, 2008; Chiba et al., 2009).”
BackgroundMethodInfluentialMiners, J. O., Knights, K. M., Houston, J. B., & Mackenzie, P. I. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.019 · Cited by 228 · cited 2×
“Better predictions of in vivo glucuronidation based on hepatocyte data support these conclusions (Miners et al., 2006).”
BackgroundResultLübberstedt, M., Müller-Vieira, U., Mayer, M., Biemel, K. M., Knöspel, F., Knobeloch, D., Nüssler, A. K., Gerlach, J. C., & Zeilinger, K. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2010.04.013 · Cited by 227 · cited 1×
“HepaRG cells have recently been proposed to serve as a potential alternative to primary hepatocytes (Turpeinen et al., 2009; Lubberstedt et al., 2011; Zanelli et al., 2012).”
BackgroundMiners, J. O., Mackenzie, P. I., & Knights, K. M. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903210716 · Cited by 226
In vitro-in vivo Extrapolation of Transporter-mediated Clearance in the Liver and Kidney
Kusuhara, H., & Sugiyama, Y. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.37 · Cited by 224 · cited 2×
“In vitro estimation of renal clearance The state of the art for in vitro models of renal clearance is not as advanced as is the case for liver clearance, although some progress has been made with pharmaceuticals (Kusuhara and Sugiyama, 2009).”
BackgroundPredicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2004) · Xenobiotica · doi:10.1080/00498250310001646353 · Cited by 219 · cited 2×
“The differences in microenvironment between the recombinant CYPs and the mammalian system can be adjusted for by using a relative activity factor (RAF) or an intersystem extrapolation factor (ISEF) (Table 2) based on comparative rates of metabolism towards the same isoform-selective probe substrate between mammalian e…”
BackgroundPrueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., & Vyas, K. P. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07382-9 · Cited by 209 · cited 2×
“Before a full implementation, however, more studies should be performed to address the known differences in enzyme expressions between Caco-2 and human intestine in vivo, not just for the expression of the specific enzyme itself, but also the relative level of expression of the enzyme compared to other enzymes and als…”
BackgroundYang, C.-H., Glover, K. P., & Han, X. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq219 · Cited by 197 · cited 1×
“However, it should at least be possible to develop a assays to identify whether a compound is a substrate for a particular transporter (Yang et al., 2010).”
BackgroundCROW, J., BORAZJANI, A., POTTER, P., & ROSS, M. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.03.002 · Cited by 181 · cited 1×
“In addition to the liver, the intestine is a key site for hydrolysis of a number of ester compounds of environmental concern that are used as pesticides and in consumer products, including pyrethroids, phthalates, and parabens (Kluwe, 1982; Imai, 2006; Crow et al., 2007).”
BackgroundCoecke, S., Ahr, H., Blaauboer, B. J., Bremer, S., Casati, S., Castell, J., Combes, R., Corvi, R., Crespi, C. L., Cunningham, M. L., et al. (2006) · Alternatives to Laboratory Animals · doi:10.1177/026119290603400113 · Cited by 180
Gómez-Lechón, M. J., Castell, J. V., & Donato, M. T. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.10.013 · Cited by 170 · cited 3×
“There have been significant improvements in the quality of human tissue preparation in recent years and also parallel advances in application strategies of those in vitro data to predict in vivo kinetics (Gomez-Lechon et al., 2007; Houston and Galetin, 2008; Chiba et al., 2009).”
BackgroundMethodDeJongh, J., Verhaar, H. J. M., & Hermens, J. L. M. (1997) · Archives of Toxicology · doi:10.1007/s002040050463 · Cited by 170 · cited 1×
“For example, simple empirical correlations have been developed for estimating the tissue partitioning of a chemical from its water solubility, vapor pressure, and octanol/water partitioning (Paterson and Mackay, 1989, DeJongh et al., 1997, Schmitt, 2008).”
BackgroundBiokinetic Modeling and in Vitro–in Vivo Extrapolations
Blaauboer, B. J. (2010) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2010.483940 · Cited by 168 · cited 3×
“However, the concentration of free chemical in an in vitro assay that elicits a certain response may differ from the nominal AC 50 value due to factors such as protein-lipid composition of the media and binding of the chemical to surfaces (Blaauboer, 2010).”
BackgroundMethods for Predicting In Vivo Pharmacokinetics Using Data from In Vitro Assays
Houston, J. B., & Galetin, A. (2008) · Current Drug Metabolism · doi:10.2174/138920008786485164 · Cited by 165 · cited 3×
“Therefore, QIVIVE for drug metabolism has largely focused on prediction of oral bioavailability and metabolic stability screening to inform the drug’s half-life (Pelkonen and Turpeinen, 2007; Houston and Galetin, 2008).”
BackgroundMethodMetabolism of Bisphenol A in Primary Cultured Hepatocytes from Mice, Rats, and Humans
Pritchett, J. J., Kuester, R. K., & Sipes, I. G. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1180 · Cited by 162 · cited 2×
“…Major detoxification by glucuronide formation Primary cultured hepatocytes Human Species differences in detoxification by conjugation Pritchett et al., 2002Sulfation Rat Mouse Chlorpyrifos/Diazinon CYPs Metabolic activation to oxon metabolites (CYPs) Microsomes Rat Use of in vitro…”
BackgroundZucco, F., Batto, A.-F., Bises, G., Chambaz, J., Chiusolo, A., Consalvo, R., Cross, H. S., Negro, G. D., Angelis, I. D., Fabre, G., et al. (2005) · Alternatives to Laboratory Animals · doi:10.1177/026119290503300618 · Cited by 161
Louisse, J., de Jong, E., van de Sandt, J. J. M., Blaauboer, B. J., Woutersen, R. A., Piersma, A. H., Rietjens, I. M. C. M., & Verwei, M. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq270 · Cited by 154 · cited 1×
“A similar approach was used to predict the in vivo doseresponse for developmental toxicity of glycol ethers in rat and man (Louisse et al., 2010).”
MethodKinetic Analysis of Furan Biotransformation by F-344 Rats in Vivo and in Vitro
Kedderis, G. L., Carfagna, M. A., Held, S. D., Batra, R., Murphy, J., & Gargas, M. L. (1993) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1993.1246 · Cited by 147 · cited 11×
“By simulating the impact of CYP2E1 induction on furan and other air pollutants that are bioactivated by CYP2E1, the importance of physiological constraints, in this case the hepatic blood flow limitation of metabolism, was demonstrated (Kedderis, 1997).”
BackgroundMethodInfluentialOverview of phthalate ester pharmacokinetics in mammalian species.
Kluwe, W. M. (1982) · Environmental Health Perspectives · doi:10.1289/ehp.82453 · Cited by 141
Precision-cut tissue slices as a tool to predict metabolism of novel drugs
Graaf, I. A. D., Groothuis, G. M., & Olinga, P. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.879 · Cited by 138 · cited 2×
“…slices are the best available system for maintaining intact, integrated metabolizing enzyme systems as well as other physiological functions, although assuring even substrate availability within the system can be a challenge (Graaf et al., 2007; Kedderis, 2007; van de Bovenkamp et al., 2008).”
BackgroundNatoli, M., Leoni, B. D., D’Agnano, I., D’Onofrio, M., Brandi, R., Arisi, I., Zucco, F., & Felsani, A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22487 · Cited by 137 · cited 1×
“In addition, many different lines and clones of Caco-2 exist, structural and functional properties of which vary depending on culture conditions (Zucco et al., 2005; Siissalo et al., 2007; Natoli et al., 2011).”
BackgroundIn vitro measurements of metabolism for application in pharmacokinetic modeling
Lipscomb, J. C., & Poet, T. S. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.01.006 · Cited by 137
The Free Hormone Hypothesis Distinction from the Free Hormone Transport Hypothesis
MENDEL, C. M. (1992) · Journal of Andrology · doi:10.1002/j.1939-4640.1992.tb01639.x · Cited by 127 · cited 1×
“The free concentration of a chemical drives both its kinetics and dynamics (Mendel, 1992).”
BackgroundFunctional expression, inhibition and induction of CYP enzymes in HepaRG cells
Turpeinen, M., Tolonen, A., Chesné, C., Guillouzo, A., Uusitalo, J., & Pelkonen, O. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.03.008 · Cited by 125
Gülden, M., Mörchel, S., & Seibert, H. (2001) · Toxicology in Vitro · doi:10.1016/s0887-2333(01)00008-x · Cited by 124 · cited 1×
“To the extent that the cells in the in vitro assay are representative of the cells in the in vivo target tissue, equal free concentration in the media and plasma will be associated with the same intracellular exposures (Gülden et al., 2001).”
BackgroundGülden, M., Mörchel, S., Tahan, S., & Seibert, H. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00085-9 · Cited by 123 · cited 1×
“…from the nominal concentration (added amount of chemical divided by volume of the media) due to factors such as protein/lipid binding in the media (Gülden et al., 2002, Seibert et al., 2002), evaporation, precipitation, and adherence of the chemical to surfaces (Blaauboer, 2010; Kramer, 2010).”
BackgroundPelkonen, O., & Turpeinen, M. (2007) · Xenobiotica · doi:10.1080/00498250701620726 · Cited by 119 · cited 3×
“Therefore, QIVIVE for drug metabolism has largely focused on prediction of oral bioavailability and metabolic stability screening to inform the drug’s half-life (Pelkonen and Turpeinen, 2007; Houston and Galetin, 2008).”
BackgroundMethodGülden, M., & Seibert, H. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00146-x · Cited by 118 · cited 3×
“In vivo plasma concentrations of the test compounds based on the in vitro ID50 (50% inhibition dose) were extrapolated using the model described by Gülden and Seibert (2003).”
BackgroundMethodIn Vitro Methods to Study Intestinal Drug Metabolism
van de Kerkhof, E. G., de Graaf, I., & Groothuis, G. M. M. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109742 · Cited by 114
Verwei, M., van Burgsteden, J. A., Krul, C. A. M., van de Sandt, J. J. M., & Freidig, A. P. (2006) · Toxicology Letters · doi:10.1016/j.toxlet.2006.01.017 · Cited by 109 · cited 2×
“ME), 2-methoxyacetic acid (2-MAA), 2-ethoxyethanol (2-EE), 2-ethoxyacetic acid (2-EAA), retinoic acid (RA), and methotrexate (MTX) using in vitro toxicity assays (Verwei et al., 2006).”
MethodMirfazaelian, A., Kim, K., Anand, S. S., Kim, H. J., Tornero‐Velez, R., Bruckner, J. V., & Fisher, J. W. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl056 · Cited by 108 · cited 2×
“Two examples of QIVIVE that incorporated esterasemediated biotransformation measured in vitro into PBPK models are provided by studies on deltamethrin (Mirfazaelian et al., 2006, Tornero-Velez et al., 2010) and chlorpyrifos/diazinon (Timchalk and Poet, 2008) (Table 3).”
MethodDrug Disposition and Liver Disease
Wilkinson, G. R., & Schenker, S. (1975) · Drug Metabolism Reviews · doi:10.3109/03602537508993754 · Cited by 106 · cited 5×
“Determinants of chemical availability for clearance In the standard description of clearance of a drug compound from blood by liver metabolism (Gillette, 1971; Rowland et al., 1973; Wilkinson and Schenker, 1975; Wilkinson and Shand, 1975), binding in the blood is assumed to be linear and the fraction unbound, fub, is…”
BackgroundMethodInfluentialChen, Y., Liu, L., Nguyen, K., & Fretland, A. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035147 · Cited by 105 · cited 4×
“, 2011), due to the difference in the intrinsic activity between the expressed system and the endogenous mammalian microsomes and the subsequent need to account for the difference as detailed below (Lipscomb and Poet, 2008; Chen et al., 2011).”
BackgroundInfluentialAnthony, A., Caldwell, J., Hutt, A. J., & Smith, R. L. (1987) · Food and Chemical Toxicology · doi:10.1016/0278-6915(87)90257-2 · Cited by 103 · cited 3×
“and human urine were reasonably consistent with the observed data, at least for the purpose of evaluating the dose-dependent changes in bioactivation, if not for predicting the absolute dose metrics (Anthony et al., 1987; Punt et al., 2008; Punt et al., 2009).”
BackgroundMethodHestermann, E. V. (2000) · Toxicological Sciences · doi:10.1093/toxsci/53.2.316 · Cited by 102 · cited 1×
“For example, the use of whole serum or serum albumin in cell-based assays can greatly alter the apparent dose-response for cellular toxicity compared to serum-free media (Hestermann et al., 2000).”
BackgroundSeibert, H., Mörchel, S., & Gülden, M. (2002) · Toxicology in Vitro · doi:10.1016/s0887-2333(02)00014-0 · Cited by 100 · cited 1×
“…from the nominal concentration (added amount of chemical divided by volume of the media) due to factors such as protein/lipid binding in the media (Gülden et al., 2002, Seibert et al., 2002), evaporation, precipitation, and adherence of the chemical to surfaces (Blaauboer, 2010; Kramer, 2010).”
BackgroundThe ECVAM Prevalidation Study on the Use of EpiDerm for Skin Corrosivity Testing
Liebsch, M., Traue, D., Barrabas, C., Spielmann, H., Uphill, P., Wilkins, S., McPherson, J. P., Wiemann, C., Kaufmann, T., Remmele, M., et al. (2000) · Alternatives to Laboratory Animals · doi:10.1177/026119290002800309 · Cited by 96 · cited 1×
“…of hepatic clearance ........................................................................................................................... 638 In vitro systems for assessing metabolism…”
Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice
Bondoc, F. Y., Bao, Z., Hu, W., Gonzalez, F. J., Wang, Y., Yang, C. S., & Hong, J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00111-2 · Cited by 94 · cited 11×
“By simulating the impact of CYP2E1 induction on furan and other air pollutants that are bioactivated by CYP2E1, the importance of physiological constraints, in this case the hepatic blood flow limitation of metabolism, was demonstrated (Kedderis, 1997).”
BackgroundMethodInfluentialMazur, C. S., Kenneke, J. F., Hess-Wilson, J. K., & Lipscomb, J. C. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034819 · Cited by 88 · cited 1×
“Intestinal glucuronidation was found to be one of the key considerations in describing BPA biokinetics for human health risk assessment of this chemical based on in vitro metabolism information (Mazur et al., 2010).”
BackgroundPrediction of toxicity from chemical structure
Barratt, M. D. (2000) · Cell Biology and Toxicology · doi:10.1023/a:1007676602908 · Cited by 86 · cited 2×
“E-mail: HClewell@thehamner.org (Received 17 October 2011; revised 25 April 2012; accepted 06 May 2012) 1040-8444 1547-6898 © 2012 Informa Healthcare USA, Inc. 10.3109/10408444.2012.692115 Critical Reviews in Toxicology”
BackgroundMethodInfluentialIn Vitrotoin VivoExtrapolation for Trichloroethylene Metabolism in Humans
Lipscomb, J. C., Fisher, J. W., Confer, P. D., & Byczkowski, J. Z. (1998) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1998.8485 · Cited by 82 · cited 3×
“In another study, to describe CYP 2E1 mediated metabolism of TCE the rate of TCE metabolism was measured as the sum of metabolites formed from initial oxidation of TCE to chloral hydrate by CYP2E1 and subsequent metabolism of chloral hydrate via ADHs and ALDHs (Lipscomb et al., 1998).”
BackgroundMethodTimchalk, C. A., & Poet, T. S. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.02.004 · Cited by 77 · cited 2×
“Two examples of QIVIVE that incorporated esterasemediated biotransformation measured in vitro into PBPK models are provided by studies on deltamethrin (Mirfazaelian et al., 2006, Tornero-Velez et al., 2010) and chlorpyrifos/diazinon (Timchalk and Poet, 2008) (Table 3).”
MethodFagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 76
Punt, A., Paini, A., Boersma, M., Freidig, A., Delatour, T., Scholz, G., Schilter, B., van Bladeren, P., & Rietjens, I. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp102 · Cited by 76 · cited 6×
“To describe one of the detoxification pathways of estragole in the PBPK model, in vitro derived glucuronidation rate constants were extrapolated to in vivo based on microsomal protein content (Punt et al., 2008; Punt et al., 2009).”
BackgroundMethodResultInfluentialZanelli, U., Caradonna, N. P., Hallifax, D., Turlizzi, E., & Houston, J. B. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042309 · Cited by 76 · cited 1×
“HepaRG cells have recently been proposed to serve as a potential alternative to primary hepatocytes (Turpeinen et al., 2009; Lubberstedt et al., 2011; Zanelli et al., 2012).”
BackgroundJONGENEELEN, F. J., & ten Berge, W. F. (2011) · The Annals of Occupational Hygiene · doi:10.1093/annhyg/mer075 · Cited by 70
Blaauboer, B. J. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00367-3 · Cited by 69 · cited 2×
“…QSAR- and in vitro-derived parameters, coupled with in vitro assays of tissue/organ toxicity, have the potential to replace in vivo animal studies for quantitative assessment of the biological activity of xenobiotics (Blaauboer, 2001a, Blaauboer et al., 2001b, Blaauboer, 2002, Blaauboer, 2003).”
BackgroundForsby, A., & Blaauboer, B. J. (2007) · Human & Experimental Toxicology · doi:10.1177/0960327106072994 · Cited by 67 · cited 1×
“The discrepancy between the observed and estimated LOELs ranged from a factor of less than two for compounds with low toxicity, to a factor of ten for chemicals of high toxicity (Forsby and Blaauboer, 2007).”
BackgroundBlaauboer, B. J., Barratt, M. D., & Houston, J. B. (1999) · Alternatives to Laboratory Animals · doi:10.1177/026119299902700211 · Cited by 59 · cited 1×
“Therefore, predictive studies on the biological activity of compounds require the integration of data on the mechanisms of action with data on pharmacokinetic behavior (Blaauboer et al., 1999, Blaauboer et al., 2000, Blaauboer, 2001a, Blaauboer, 2002, Blaauboer, 2003).”
BackgroundDe Buck, S. S., & Mackie, C. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.865 · Cited by 58
Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D. A., Cox, T., & Kedderis, G. L. (2003) · Risk Analysis · doi:10.1111/j.0272-4332.2003.00397.x · Cited by 57 · cited 3×
“From the QIVIVE point of view, a major advantage of the recombinant system is the capability of providing human variability information when combined with enzyme abundance data (Lipscomb et al., 2003; Punt et al., 2010).”
BackgroundExtrapolation of in vitro enzyme induction data to humans in vivo
Kedderis, G. L. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00076-8 · Cited by 57
Siissalo, S., Laitinen, L., Koljonen, M., Vellonen, K., Kortejärvi, H., Urtti, A. O., Hirvonen, J. J., & Kaukonen, A. M. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.017 · Cited by 56 · cited 3×
“…these Caco-2 clones could be useful for screening or evaluating specific functions of intestinal epithelial cells, such as function of Pgp (Hochman et al., 2000; Siissalo et al., 2007), this lack of consistency in the model system is one of the major challenges in using this model for IVIVE.”
BackgroundEvaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model
Tornero‐Velez, R., Mirfazaelian, A., Kim, K., Anand, S. S., Kim, H. J., Haines, W. T., Bruckner, J. V., & Fisher, J. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.034 · Cited by 54 · cited 1×
“Two examples of QIVIVE that incorporated esterasemediated biotransformation measured in vitro into PBPK models are provided by studies on deltamethrin (Mirfazaelian et al., 2006, Tornero-Velez et al., 2010) and chlorpyrifos/diazinon (Timchalk and Poet, 2008) (Table 3).”
Methodvan de Bovenkamp, M., Groothuis, G. M. M., Meijer, D. K. F., & Olinga, P. (2008) · Toxicology in Vitro · doi:10.1016/j.tiv.2007.11.019 · Cited by 53 · cited 1×
“…slices are the best available system for maintaining intact, integrated metabolizing enzyme systems as well as other physiological functions, although assuring even substrate availability within the system can be a challenge (Graaf et al., 2007; Kedderis, 2007; van de Bovenkamp et al., 2008).”
BackgroundIn vitro methods in human drug biotransformation research: Implications for cancer chemotherapy
Hariparsad, N., Sane, R. S., Strom, S. C., & Desai, P. B. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.049 · Cited by 53 · cited 5×
“…expressed enzymes are often applied to obtain qualitative information on metabolism including the contribution of a single metabolic enzyme or a combination of multiple isozymes to the biotransformation of the chemical and identification of potential metabolites (Hariparsad et al., 2006).”
BackgroundMethodInfluentialPlowchalk, D. R. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.60 · Cited by 51 · cited 1×
“An example of this approach has been described in the case of a PBPK model for estradiol (Plowchalk and Teeguarden, 2002).”
MethodLoizou, G. D., Jones, K., Akrill, P., Dyne, D., & Cocker, J. (1999) · Toxicological Sciences · doi:10.1093/toxsci/48.2.170 · Cited by 50 · cited 1×
“A similar QIVIVE approach was conducted for m-xylene employing the vial equilibration method with hepatic microsomes from rats and humans (Loizou et al., 1999).”
MethodGülden, M., Dierickx, P. J., & Seibert, H. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.02.002 · Cited by 48 · cited 1×
“…vivo plasma concentration that would be expected to elicit a target-tissue response similar to the cellular response in the in vitro assay, the free fraction must be determined in both the in vitro and in vivo exposures (Gülden and Seibert, 2003, Teeguarden and Barton, 2004, Gülden et al., 2006).”
BackgroundTeeguarden, J., & Barton, H. A. (2004) · Risk Analysis · doi:10.1111/j.0272-4332.2004.00473.x · Cited by 48 · cited 4×
“E-mail: HClewell@thehamner.org (Received 17 October 2011; revised 25 April 2012; accepted 06 May 2012) 1040-8444 1547-6898 © 2012 Informa Healthcare USA, Inc. 10.3109/10408444.2012.692115 Critical Reviews in Toxicology”
BackgroundInfluentialPloemen, J.-P. H. T. M., Wormhoudt, L. W., Haenen, G. R. M. M., Oudshoorn, M. J., Commandeur, J. N. M., Vermeulen, N. P. E., de Waziers, I., Beaune, P. H., Watabe, T., & van BLADEREN, P. J. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8004 · Cited by 47 · cited 3×
“Another example with ethylene bromide demonstrated QIVIVE for GST mediated formation of a carcinogenic metabolite, while metabolism by CYPs represented detoxification (Ploemen et al., 1997).”
BackgroundSiissalo, S., Laine, L., Tolonen, A., Kaukonen, A. M., Finel, M., & Hirvonen, J. J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.044 · Cited by 43 · cited 4×
“, UGTs), they are still only qualitatively comparable (Siissalo et al., 2010).”
BackgroundResultInfluentialIn Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters
Kusama, M., Toshimoto, K., Maeda, K., Hirai, Y., Imai, S., Chiba, K., Akiyama, Y., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032789 · Cited by 39 · cited 1×
“Qualitative prediction of whether a drug was likely to be cleared by metabolism (including the CYP isozyme involved) or by urinary excretion on the basis of its physicochemical properties has recently been demonstrated (Kusama et al., 2010).”
BackgroundGülden, M., & Seibert, H. (1997) · Toxicology in Vitro · doi:10.1016/s0887-2333(97)00042-8 · Cited by 39 · cited 2×
“Protein binding can be a key determinant of disposition (Gülden and Seibert, 1997), affecting compound availability for uptake into cells in vitro as well as target tissues in vivo.”
BackgroundStudying cytochrome P450 kinetics in drug metabolism
Kramer, M. A., & Tracy, T. S. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.591 · Cited by 35
The Necessity of Biokinetic Information in the Interpretation of In Vitro Toxicity Data
Blaauboer, B. J. (2002) · Alternatives to Laboratory Animals · doi:10.1177/026119290203002s13 · Cited by 35 · cited 2×
“…QSAR- and in vitro-derived parameters, coupled with in vitro assays of tissue/organ toxicity, have the potential to replace in vivo animal studies for quantitative assessment of the biological activity of xenobiotics (Blaauboer, 2001a, Blaauboer et al., 2001b, Blaauboer, 2002, Blaauboer, 2003).”
BackgroundSiissalo, S., Zhang, H., Stilgenbauer, E., Kaukonen, A. M., Hirvonen, J. J., & Finel, M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.022335 · Cited by 32 · cited 2×
“…contributors of intestinal metabolism and their expression levels can be modified to better reflect in vivo conditions based on the culture conditions for this cell line or possibly using a co-culture system with hepatocytes (Hochman et al., 2000; Siissalo et al., 2008; Siissalo et al., 2010).”
BackgroundApplication of in vitro biotransformation data and pharmacokinetic modeling to risk assessment
Kedderis, G. L., & Lipscomb, J. C. (2001) · Toxicology and Industrial Health · doi:10.1191/0748233701th119oa · Cited by 28
Incorporating human interindividual biotransformation variance in health risk assessment
Lipscomb, J. C., & Kedderis, G. L. (2002) · The Science of The Total Environment · doi:10.1016/s0048-9697(01)01115-9 · Cited by 26
MEGen: a physiologically based pharmacokinetic model generator
Loizou, G. D. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00056 · Cited by 24 · cited 2×
“Although generic modeling platforms are available for some classes of compounds, e.g., IndusChemFate (Jongeneelen and Berge, 2011) and MEGen (Loizou and Hogg, 2011), the development of generic models has not been as extensive as in the pharmaceutical area.”
BackgroundHissink, A. M., van Ommen, B., Krüse, J., & van BLADEREN, P. J. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8184 · Cited by 23 · cited 3×
“…1,2-DCB at various doses when the in vitro derived Vmax was used in the PBPK model, the discrepancy was considered to be in the acceptable range given some limitations in the in vitro measurements and the fact that the model structure did not include extrahepatic metabolism (Hissink et al., 1997).”
MethodInfluentialPunt, A., Jeurissen, S. M. F., Boersma, M. G., Delatour, T., Scholz, G., Schilter, B., van BLADEREN, P. J., & Rietjens, I. M. C. M. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp272 · Cited by 22 · cited 7×
“Recombinant enzymes are frequently used in combination with other in vitro systems, such as microsomes, to fully address the human variability issue for QIVIVE (Punt et al., 2010).”
BackgroundMethodInfluentialMeasuring, modeling, and increasing the free Concentration of test Chemicals in cell assays
Kramer, N. I. (2010) · Utrecht University Repository (Utrecht University) · Cited by 21
Hissink, E. M., Bogaards, J. J. P., Freidig, A. P., Commandeur, J. N. M., Vermeulen, N. P. E., & van BLADEREN, P. J. (2002) · Environmental Toxicology and Pharmacology · doi:10.1016/s1382-6689(02)00019-4 · Cited by 19 · cited 1×
“A few years later, another group reported a TCE QIVIVE in rats using an alternative approach employing a combination of in vitro assays with expressed CYP and purified GST enzymes (Hissink et al., 2002).”
MethodYoon, M., Madden, M. C., & Barton, H. A. (2007) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390701384684 · Cited by 19 · cited 1×
“However, for CYP2E1 mediated metabolism of VOCs, the impact of extrahepatic metabolism is not expected to be significant (Yoon et al., 2007).”
BackgroundSelf-citationThe integrated use of alternative methods in toxicological risk evaluation.
Blaauboer, B. J., Barratt, M. D., & Houston, B. (1998) · Cited by 19
Cited by
Schirinzi, G. F., Pérez-Pomeda, I., Sanchís, J., Rossini, C., Farré, M., & Barceló, D. (2017) · Environmental Research · doi:10.1016/j.envres.2017.08.043 · Cited by 902
Kidney-on-a-Chip technology for drug-induced nephrotoxicity screening
Wilmer, M. J., Ng, C. P., Lanz, H. L., Vulto, P., Suter-Dick, L., & Masereeuw, R. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.11.001 · Cited by 354
Ciallella, H. L., & Zhu, H. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00393 · Cited by 227
“106 Mechanism-driven modeling, initiated and advanced by the concept of the adverse outcome pathway (AOP), allows for mechanistic extrapolation of toxicity evaluations of new compounds, filling a critical need of applying alternatives for regulatory toxicology studies.”
BackgroundIn vitro models of medulloblastoma: Choosing the right tool for the job
Ivanov, D. P., Coyle, B., Walker, D. A., & Grabowska, A. M. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.07.028 · Cited by 227
Bal-Price, A. (2018) · ALTEX · doi:10.14573/altex.1712081 · Cited by 207
Metadata
- Authors
- Yoon, M., Campbell, J. L., Andersen, M. E., & Clewell, H. J.
- Venue
- Critical Reviews in Toxicology
- Publisher
- Informa UK Limited
- Published
- 2012-06-06
- Volume
- 42
- Issue
- 8
- Pages
- 633-652
- ISSN
- 0045-6446 (ISSN-L)
- 1040-8444
- 1547-6898
- OpenAlex
- W1982484840
- Cited by
- 216
- References
- 98
- FWCI
- 23.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.